PURPOSE To analyze the efficacy, safety, predictability, and stability in hyperopic presbyopic laser in situ keratomileusis (LASIK) surgeries with the TENEO 317 algorithm (Bausch & Lomb Technolas, Munich, Germany). METHODS Eighty eyes from 40 patients who underwent hyperopic and presbyopic LASIK in this retrospective, observational, and longitudinal study were included. All patients had a 24-month follow-up. Excimer laser treatment was performed with TECNOLAS Perfect Vision GmbH TENEO 317 software version 1.25 (Bausch & Lomb) with the PROSCAN platform for the distance dominant eye and the SUPRACOR mild platform for the near dominant eye. RESULTS Mean age was 53.90 ± 4.84 years (range: 42 to 66 years). Postoperative uncorrected distance visual acuity (UDVA) was 0.00 ± 0.04 (20/19.97) for the dominant eye and 0.14 ± 0.05 (20/27.65) for the non-dominant eye. Postoperative uncorrected near visual acuity was 0.51 ± 0.17 (J9) for the dominant eye and 0.09 ± 0.06 (J1.5) for the non-dominant eye, whereas 2.5% of non-dominant eyes lost two lines of corrected distance visual acuity. Half of non-dominant eyes lost one line, and 2.5% of dominant and non-dominant eyes changed 0.50 D or more between 3 and 24 months. CONCLUSIONS PROSCAN surgery in the dominant eye and SUPRACOR surgery in the non-dominant eye using the TENEO 317 algorithm demonstrated that the hyperopic presbyopic excimer laser surgery technique resulted in acceptable and stable outcomes after 24 months of follow-up. [J Refract Surg. 2019;35(9):591-598.].

中文翻译：

---

SUPRACOR TENEO 317 LASIK用于远视眼老花眼的屈光和视觉结果：24个月随访。

目的使用TENEO 317算法（Bausch＆Lomb Technolas，慕尼黑，德国）分析远视老花激光原位角膜磨镶术（LASIK）的疗效，安全性，可预测性和稳定性。方法这项回顾性，观察性和纵向性研究纳入了40例接受远视和老花LASIK手术的患者的80只眼。所有患者均进行了24个月的随访。使用TECNOLAS Perfect Vision GmbH TENEO 317软件版本1.25（Bausch＆Lomb）进行准分子激光治疗，其中PROSCAN平台用于远距离优势眼，SUPRACOR温和平台用于近优势眼。结果平均年龄为53.90±4.84岁（范围：42至66岁）。优势眼的术后未矫正远视力（UDVA）为0.00±0.04（20 / 19.97），而主眼为0.14±0.05（20/27）。65）为非优势眼。优势眼的术后未矫正近视力为0.51±0.17（J9），非优势眼为0.09±0.06（J1.5），而2.5％的非优势眼丧失了两行校正后的远视力。在3至24个月之间，一半的非优势眼失去了一条线，而占优势和非优势眼的2.5％改变了0.50 D或更多。结论使用TENEO 317算法进行的优势眼PROSCAN手术和非优势眼SUPRACOR手术证明，远视老花眼准分子激光手术技术在随访24个月后可产生可接受且稳定的结果。[J Refract Surg。2019; 35（9）：591-598。]。5％的非优势眼丧失了两行矫正的远距离视敏度。在3至24个月之间，一半的非优势眼失去了一条线，而占优势和非优势眼的2.5％改变了0.50 D或更多。结论使用TENEO 317算法进行的优势眼PROSCAN手术和非优势眼SUPRACOR手术证明，远视老花眼准分子激光手术技术在随访24个月后可产生可接受且稳定的结果。[J Refract Surg。2019; 35（9）：591-598。]。5％的非优势眼丧失了两行矫正的远距离视敏度。在3至24个月之间，一半的非优势眼失去了一条线，而占优势和非优势眼的2.5％改变了0.50 D或更多。结论使用TENEO 317算法进行的优势眼PROSCAN手术和非优势眼SUPRACOR手术证明，远视老花眼准分子激光手术技术在随访24个月后可产生可接受且稳定的结果。[J Refract Surg。2019; 35（9）：591-598。]。结论使用TENEO 317算法进行的优势眼PROSCAN手术和非优势眼的SUPRACOR手术证明，远视老花准分子激光手术技术经过24个月的随访，结果可接受且稳定。[J Refract Surg。2019; 35（9）：591-598。]。结论使用TENEO 317算法进行的优势眼PROSCAN手术和非优势眼的SUPRACOR手术证明，远视老花准分子激光手术技术经过24个月的随访，结果可接受且稳定。[J Refract Surg。2019; 35（9）：591-598。]。